Zobrazeno 1 - 10
of 180
pro vyhledávání: '"David R, Staskin"'
Autor:
Jeffrey Frankel, David R. Staskin, Susann Varano, Rachael Jankowich, Denise Shortino, Paul N. Mudd
Publikováno v:
Drugs & Aging
Background Overactive bladder (OAB) is common among older adults. The efficacy and safety of vibegron for the treatment of OAB were demonstrated in the international, phase III EMPOWUR trial. This subpopulation analysis from EMPOWUR assessed the effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f13652957bd5e6219fee7bf4b3d0785
http://europepmc.org/articles/PMC7882560
http://europepmc.org/articles/PMC7882560
Publikováno v:
Drugs & Aging
Background In older patients with overactive bladder (OAB), mirabegron, a β3-adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk–benefit profile. Objectives Our objective was to further examine the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::952cabf2e7ecf15f6f4812d7ae1a0624
https://doi.org/10.1007/s40266-020-00783-w
https://doi.org/10.1007/s40266-020-00783-w
Autor:
Nurul Choudhury, Sender Herschorn, Matthias Stoelzel, John Heesakkers, Christopher R. Chapple, Linda Cardozo, Francisco Cruz, Emad Siddiqui, David R. Staskin
Publikováno v:
European Urology, 77, 119-128
European Urology, 77, 1, pp. 119-128
Transl Androl Urol
European Urology, 77, 1, pp. 119-128
Transl Androl Urol
Mirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms.To summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms.Pooled data analysed from 10 phase 2-4, doub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f9a28e569df1a3a10395e6350312a6
https://doi.org/10.1016/j.eururo.2019.09.024
https://doi.org/10.1016/j.eururo.2019.09.024
Autor:
Michael Kennelly, David R. Staskin, Paul N. Mudd, Matt T. Rosenberg, Denise Shortino, Susann Varano, Jeffrey Frankel, Rachael Jankowich, Diane K. Newman
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Overactive bladder (OAB) is characterized by urinary urgency, often accompanied by frequency and nocturia, with or without urge urinary incontinence (UUI), referred to as...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::851091d4e2b0ab0fbd7a0b3ac0402923
https://doi.org/10.1097/ju.0000000000002103.15
https://doi.org/10.1097/ju.0000000000002103.15
Autor:
Christopher R. Chapple, Elizabeth R. Mueller, Emad Siddiqui, Christian Gratzke, Matthias Stoelzel, Dudley Robinson, Catherine Rolland, David R. Staskin, Rob van Maanen
Publikováno v:
European Urology. 76:767-779
Oral pharmacotherapy consisting of antimuscarinics, β3-adrenoreceptor agonists, or combinations of these agents forms the mainstay of overactive bladder (OAB) management.To evaluate the efficacy and safety of combination therapy in patients with OAB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b8c2d9538d23465f5739711a5bd465
https://doi.org/10.1016/j.eururo.2019.07.010
https://doi.org/10.1016/j.eururo.2019.07.010
Autor:
Jeffrey Frankel, Susann Varano, Denise Shortino, Paul N. Mudd, David R. Staskin, Rachael Jankowich
Publikováno v:
International Journal of Clinical Practice
Background Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β3‐adrenergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomised, double‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d3fd90f6cfa035be4373072df3fad0
http://europepmc.org/articles/PMC8244055
http://europepmc.org/articles/PMC8244055
Autor:
Paul N. Mudd, Rachael Jankowich, David R. Staskin, Susann Varano, Denise Shortino, Jeffrey Frankel
Publikováno v:
The Journal of urology. 205(5)
The long-term safety, tolerability and efficacy of vibegron in adults with overactive bladder were evaluated in the 40-week phase 3 EMPOWUR extension study.Patients who completed 12 weeks of once-daily vibegron 75 mg or tolterodine 4 mg extended rele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c90ad140865404fbde0459037fab8a0
https://pubmed.ncbi.nlm.nih.gov/33687276
https://pubmed.ncbi.nlm.nih.gov/33687276
Autor:
David R. Staskin, Denise Shortino, Rachael Jankowich, Paul N. Mudd, Susann Varano, Jeffrey Frankel
Publikováno v:
The Journal of urology. 204(2)
We assessed efficacy, safety and tolerability of vibegron, a novel, potent, highly selective βAdult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, placebo or extended-release 4 mg exte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a21b399a0841328deac6449e0ecea72
https://pubmed.ncbi.nlm.nih.gov/32436759
https://pubmed.ncbi.nlm.nih.gov/32436759
Autor:
David R. Staskin, Kevin T. McVary, Sender Herschorn, Christopher R. Chapple, John Hairston, Steven A. Kaplan, Steve Foley, Nurul Choudhury, Carol R. Schermer, Javier Cambronero Santos, Rita M Kristy
Publikováno v:
Journal of Urology
Journal of Urology, Elsevier, 2020, 203 (6), pp.1171-1171. ⟨10.1097/ju.0000000000000738.01⟩
Journal of Urology, Elsevier, 2020, 203 (6), pp.1171-1171. ⟨10.1097/ju.0000000000000738.01⟩
PLUS investigated the efficacy and safety of mirabegron add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying lower urinary tract symptoms attributable to benign prostatic hyperplasia.In this phase 4 study a 4-wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9120fbe0f5a8161fe87a79b60473390
https://hal.archives-ouvertes.fr/hal-03228620
https://hal.archives-ouvertes.fr/hal-03228620
Autor:
Carol R. Schermer, Sender Herschorn, David R. Staskin, Katherine Gooch, Le Mai Tu, Terry Walsh, Jonathan Fialkov
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes
Background The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB). In this a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::848d258c8661d7fb9b27748e24c14699
http://link.springer.com/article/10.1186/s12955-018-0892-0
http://link.springer.com/article/10.1186/s12955-018-0892-0